Werewolf Therapeutics Welcomes Industry Veteran Steven Bloom as CBO Amid Key Milestones

Werewolf Therapeutics has tapped seasoned life sciences executive Steven Bloom as its new Chief Business Officer, signaling a strategic push forward as the company approaches major clinical milestones. With over 35 years of experience across biotech, pharma, and strategic consulting, Bloom is poised to help guide the company through a pivotal time. Werewolf’s lead candidate, WTX-124, is advancing in its Phase 1/1b trial with promising interim data expected this year, while its PREDATOR platform continues to generate novel immunotherapies aimed at redefining cancer treatment.

CEO Daniel J. Hicklin, Ph.D., emphasized Bloom’s strong track record in business development and corporate strategy, calling him a perfect fit for the company’s evolving journey. Bloom, previously CBO at Vincerx Pharma, expressed excitement about Werewolf’s science and mission, particularly its goal of activating the immune system against tumors while minimizing side effects. With Bloom on board and a deep pipeline in motion, Werewolf is setting the stage for potentially transformative progress in oncology and beyond.